Zhittya is a Nevada (USA)-based biotechnology company, working to treat diseases which are responsible for the deaths of millions throughout the world. A lack of blood flow is responsible for varied and heterogeneous diseases ranging from coronary artery disease, stroke, diabetic foot ulcers, and vascular dementia

A lack of blood flow is also speculated to be the cause of other neurodegenerative diseases such as Parkinson’s Disease and Alzheimer’s disease, where Zhittya has been conducting research to potential treat these diseases.

Zhittya Genesis Medicine’s administration has expended over 20 years and $150,000,000 USD in developing FGF-1. This molecule is capable of growing new blood vessels in ischemic tissue in a process known as angiogenesis. By growing new blood vessels in the human body, Zhittya believes that FGF-1 could reverse the root causes of those aforementioned vascular diseases by reestablishing the blood flow in the parts of the body that need it most.

FGF-1 is a naturally-occuring biological protein responsible for the growth of new blood vessels in the human body, known as angiogenesis, and can promote the growth of new neurons, known as neurogenesis.

FGF-1 is the principle molecule responsible for natural-angiogenesis. Natural angiogenesis, the growth of new blood vessels, occurs every time you get a cut, scrape, or other injury. The FGF-1 will promote blood vessel growth to heal the area effected by the traumatic event.

Zhittya believes that slow and debilitating diseases that do not have the initial-traumatic event, such as the case in diseases like coronary artery disease and vascular dementia, that the body is unable to make enough FGF-1 to effectively heal the area.

By introducing FGF-1, we believe that we can are able to replenish the blood supply to the areas lacking proper perfusion, thereby treating the disease in the affected area. As seen in the following slides, FGF-1, was able to do exactly that. FGF-1 grew new blood vessels in individuals suffering from a coronary artery disease in a US FDA Phase IIA Clinical Trial. In the image you can see how FGF-1 was able to grow around blocked arteries in the heart and relieve no-option heart patients of some of their symptoms.